Compare JetBlue Airways Corporation (JBLU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Tango Therapeutics Inc. — how do they compare? JetBlue Airways Corporation trades at $3.03 (market cap $1.26B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 3× JetBlue Airways Corporation's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Tango Therapeutics Inc. for 0 Days on average.
| JBLU | TNGX | |
|---|---|---|
Market Cap | $1.26B | $3.75B |
Volume | 40,642,525 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $6.46 | $32.90 |
52-Week Low | $3.01 | $7.50 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.63B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.01, down 16.85% in the last 24 hours, reflecting significant bearish pressure. The stock exhibits weak fundamentals with a negative net income margin of -9.32% and consecutive quarterly losses, though it beat EPS expectations in Q2 2026. Technical indicators are predominantly bearish, with the stock trading near key support levels. Recent news highlights expansion efforts like new routes to Colombia and the launch of BlueFirst premium seating, aiming to boost revenue amid industry challenges.
The outlook remains challenging due to persistent losses, high debt levels, and elevated fuel costs. While analyst consensus suggests a hold rating with a $5.89 price target implying potential upside, risks from competitive pressures and macroeconomic factors dominate. Investment appeal is limited to speculative positions betting on a operational turnaround despite current headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
